Abilify sNDA For Major Depressive Disorder Gets Priority Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol/Otsuka are seeking a broader indication for the atypical antipsychotic for MDD as adjunctive to antidepressant therapy.
You may also be interested in...
Bristol/Otsuka’s Abilify Gets FDA Nod For Use In Combination With Antidepressants
Aripiprazole becomes first drug approved as add-on treatment for major depressive disorder.
Bristol/Otsuka’s Abilify Gets FDA Nod For Use In Combination With Antidepressants
Aripiprazole becomes first drug approved as add-on treatment for major depressive disorder.
Abilify Approval For Teens Is Bristol/Otsuka’s Latest Step In Franchise Expansion
Approval of the atypical antipsychotic for schizophrenia patients ages 13-17 comes more than two months after J&J’s Risperdal was cleared for adolescent schizophrenia.